EN DE

Madame Bioscience Public Company (MADAME) Fair Value & Analysis

Consumer Defensive · TH · Market cap 517M THB

MB Madame Bioscience Public Company MADAME · BK
Price0.8300 THB
Fair Value0.8160 THB
Upside-1.7%
Quality40/100
Watch Madame Bioscience Public Company for free, get notified when fair value or trend changes. Watch for free
Weak Growth
Loss-making · -10.5% net margin
Low debt · negative free cash flow
Mixed vs. peers (4/10)
Narrow moat 21/100
Evidence: Medium Range 0.6120 THB – 1.02 THB Share as image

Fair value as of: Jul 19, 2026

From 8 valuation models · updated 22 days ago

Share price +66.0% over the past month.

Below-average quality, currently priced close to our fair value.

What matters now

  • The price sits close to our fair value, market and models broadly agree here, little valuation tension.
  • Our model range runs from 0.6120 THB (bear) to 1.02 THB (bull), base 0.8160 THB. The closer the price sits to the lower half, the larger the margin of safety.
  • Quality 40/100 (below-average quality) with medium evidence: read the verdict with care.
Share this valuation: 𝕏 WhatsApp

Price vs Fair Value (5 years)

6.60 THB 0.4300 THB Fair Value 0.8160 THB Mar 2021 Aug 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 19, 2026.

How to read this chart

60‑month range 0.4300 THB – 6.60 THB · fair‑value band 0.6120 THB – 1.02 THB · the 0.8300 THB price screens above the 0.8160 THB fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 19, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Madame Bioscience Public Company (MADAME) currently trades at 0.8300 THB, while our model-based Fair Value estimate is 0.8160 THB, implying the stock looks roughly 1.7% fairly valued today. The Quality Score stands at 40/100 (below-average quality), in the Consumer Defensive sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: medium).

Over the trailing twelve months, Madame Bioscience Public Company generated revenue of 1.5B THB at a net margin of -10.5%. Revenue grew 15.4% year over year. It earns a return on equity of -20.4%. Net debt stands at 60.0M THB. Fundamentals as of Jul 19, 2026

Our scenario range runs from 0.6120 THB (bear case) to 1.02 THB (bull case); at 0.8300 THB, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 31% below its 52-week high and 102% above its 52-week low, currently above its 200-day average. For context, the median of 10 Consumer Defensive peers we cover trades at -3% fair-value upside, at -2%, MADAME screens cheaper than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Model Bear Bear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull Bull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence
Highest evidence
Residual Income 0.6900 THB 0.6900 THB 0.6600 THB 76
Growth-Adj P/E 0.6000 THB 0.8600 THB 1.12 THB 68
P/E Multiple 0.8500 THB 1.13 THB 1.42 THB 63
All 8 models by family
DCF Models
Owner Earnings 1.03 THB 1.33 THB 1.83 THB 31
Earnings-Based
Graham-Dodd 0.3900 THB 0.4700 THB 0.5300 THB 54
Multiples
P/E Multiple 0.8500 THB 1.13 THB 1.42 THB 63
P/S Multiple 0.7200 THB 0.9600 THB 1.20 THB 58
P/B Multiple 0.7200 THB 0.9600 THB 1.20 THB 55
Asset-Based
NCAV (Graham) 0.4600 THB 0.6200 THB 0.9300 THB 50
Economic Profit
Residual Income 0.6900 THB 0.6900 THB 0.6600 THB 76
Growth Earnings
Growth-Adj P/E 0.6000 THB 0.8600 THB 1.12 THB 68

Widest divergence: DCF Models (1.33 THB) versus Earnings-Based (0.4700 THB). Highest evidence: Residual Income (76).

Notify me when MADAME reaches fair value

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.

Key figures & financial health

Revenue (TTM) 1.5B THB
Revenue growth (YoY) +15.4%
Net margin -10.5%
Return on equity -20.4%
Free cash flow −4.6M THB FY2025
Operating margin 6.4%
More key figures
EPS (TTM) -0.2000 THB
EPS growth (YoY) -90.6%
Net debt 60.0M THB FY2025

Figures from reported company fundamentals · as of Jul 19, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 40/100

Of which business quality 41 · Market factors (momentum, volatility) 51

Profitability 44
Margins and returns on capital today
Quality Growth 50
Are margins and returns improving?
Cashflow 16
Earnings quality: real cash, not paper profit
Fin. Strength 53
Balance sheet, leverage, solvency risk
Investment 98
Disciplined investing over empire-building
Low Volatility 50
Calm price path (market factor)
Momentum 62
Price trend over the last 3–12 months (market factor)
52W Momentum 32
Distance to the 52-week high (market factor)
Net Issuance 0
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

About the company

Madame Bioscience Public Company Limited, together with its subsidiaries, engages in the food business in Thailand. It operates through Packaging Business, Retail Sales of Cosmetics, Food Business, and Other Business segments.

Full company description

Madame Bioscience Public Company Limited, together with its subsidiaries, engages in the food business in Thailand. It operates through Packaging Business, Retail Sales of Cosmetics, Food Business, and Other Business segments. The company offers various food products, including frozen processed and ready-to-eat food, chilled food, plant-based food, hemp food, processed food, and sauces under the Kitchen Plus and Look Chin Tip brands. It also provides flexible packaging, polyethylene terephthalate bottles, and food packaging trays for packaged food and beverages. In addition, the company engages in the manufacture and sale of plastic packaging, seafood, and processed meat; retail sale of cosmetics; advertising rental services in gas stations; restaurant business; network marketing; and trading activities. The company was formerly known as Global Consumer Public Company Limited and changed its name to Madame Bioscience Public Company Limited in July 2025. Madame Bioscience Public Company Limited was founded in 1987 and is headquartered in Bangkok, Thailand.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Madame Bioscience Public Company reported revenue of 1.5B THB in FY2025 versus 1.9B THB in FY2021, a compound −5.6%/yr. Reported net income was 45.8M THB in FY2025.

Growth Quality 14/100
Revenue growth is weak, negative or inconsistent.
Latest Revenue (FY 2025)
1.5B THB
Latest YoY
−30.4%
Avg. growth/yr (3Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
−12.8%
Revenue −5.6%/yr
FY21 1.9B THB
FY22 2.2B THB
FY23 2.3B THB
FY24 2.1B THB
FY25 1.5B THB
Net income
FY21 −152M THB
FY22 −422M THB
FY23 −406M THB
FY24 −332M THB
FY25 45.8M THB

Watch MADAME: get an alert when its fair value changes →

Share or link this analysis
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cite: Fair Value Calculator (2026). "Madame Bioscience Public Company Fair Value". https://www.fairvalue-calculator.com/stock/MADAME

Peer Group

Packaged Foods · 649 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Quality Score 40 · Bottom 25%
Fair Value upside −2% · Above median
Return on assets -17% · Bottom 25%
Net margin (TTM) -11% · Bottom 25%
Operating margin (TTM) 6% · Above median
Revenue growth 15% · Top 25%
Debt / equity 0.19× · Higher than median

Valuation Multiples vs Packaged Foods median · lower = cheaper

P/S (TTM) 0.01× · Cheaper than 75% of peers
PEG 2.50× · Pricier than 75% of peers

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 31 · sector 28
FUTURE 77 · sector 20
PAST 0 · sector 27
HEALTH 91 · sector 96
DIVIDEND 0 · sector 47

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Packaged Foods stocks, each showing price versus our Fair Value estimate (as of Jul 19, 2026).

Stock Price Fair Value vs Fair Value
Nestlé India Limited NESTLEIND ₹1,427 ₹362.37 -75%
Britannia Industries Limited BRITANNIA ₹5,413 ₹1,870 -65%
Tata Consumer Products Limited TATACONSUM ₹1,089 ₹327.27 -70%
PT Indofood CBP Sukses Makmur Tbk ICBP 6,650 IDR 15,757 IDR +137%
Samyang Foods Co 003230 1,139,000 KRW 1,010,543 KRW -11%
Patanjali Foods Limited PATANJALI ₹413.80 ₹157.04 -62%
Vietnam Dairy Products Joint Stock Company VNM 58,500 VND 68,259 VND +17%
PT Mayora Indah Tbk, MYOR 1,750 IDR 2,699 IDR +54%
PT Cisarua Mountain Dairy Tbk CMRY 4,490 IDR 4,355 IDR -3%
Nongshim Co 004370 348,500 KRW 530,619 KRW +52%

Compare Madame Bioscience Public Company with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Consumer Defensive stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Frequently asked questions

Is Madame Bioscience Public Company (MADAME) overvalued or undervalued?
As of Jul 19, 2026, our model estimates a fair value of 0.8160 THB versus a price of 0.8300 THB, about −2% (fairly valued).
What is the fair value of MADAME?
Our model-based fair value for Madame Bioscience Public Company is 0.8160 THB (as of Jul 19, 2026), built from audited fundamentals. The current price is 0.8300 THB.
What is the quality score of MADAME?
Madame Bioscience Public Company has a Quality Score of 40/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the revenue of Madame Bioscience Public Company (MADAME)?
Madame Bioscience Public Company reported trailing-twelve-month revenue of about 1.5B THB (latest available figure, as of Jul 19, 2026).
What is the net profit margin of MADAME?
The net profit margin of Madame Bioscience Public Company is about -10.5%, meaning it is currently running at a net loss. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.

14 days Pro free · no card

Track Madame Bioscience Public Company and try Pro for 14 days

One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.

Zero risk: nothing is ever charged. After 14 days you decide whether to stay.